Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

Inclusion Criteria: 1. Able to understand the study and voluntarily sign informed consent. 2. Age: 60\~75 years old, gender unlimited. 3. Patients diagnosed with acute myeloid leukemia according to "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" who haven't been treated. 4. Eastern Cooperative Oncology Group (ECOG) physical state score: 0-2. 5. Fit for intensive chemotherapy. 6. The function of main organs should meet the following standards before treatment: Kidney: serum creatinine ≤ 2× upper limit of normal range (ULN); Liver: total bilirubin ≤ 1.5 × ULN, AST and ALT ≤ 2.5× ULN; Heart: myocardial enzymes ≤ 2× ULN and normal ejection fraction by cardiac color doppler ultrasound Exclusion Criteria: 1. Patients with acute promyelocytic leukemia 2. Patients with RUNX1::RUNX1T1 or CBFB::MYH11 fusion gene 3. Patients with BCR::ABL fusion gene 4. Patients who have received a prior treatment for AML with chemotherapy, hypomethylating agents or venetoclax before. 5. Patients with concurrent malignant tumors requiring treatment 6. Patients with active heart disease defined as one or more of the following: (1) Uncontrolled or symptomatic angina pectoris;(2) A myocardial infarction 6 months before enrolled; (3)Arrhythmia needed medication or with severe clinical symptoms;(4)Uncontrolled or symptomatic congestive heart failure (NYHA\> grade 2);(5)Left ventricular ejection fraction below the lower limit of the normal range. 7. Uncontrolled active serious infections that could, in the investigator's opinion, potentially interfere with the completion of treatment